Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-OLE: Mavacamten Extension in oHCM
NCT03496168Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Started Apr 2018; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03496168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496168.